The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy
Open accessAbstract
Purpose. To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa. Patients and Methods. In this open-label, multicenter trial, 187 patients with chemotherapy-related anemia (Hb <11 g/dl; serum ferritin ≥100 ng/ml or transferrin saturation ≥15%) scheduled to receive chemotherapy and epoetin alfa (40,000 U subcutaneously weekly) were randomized to 8 weeks of 125 mg of IV FG weekly, 325 mg of oral ferrous sulfate three times daily, or no iron. The primary outcome was a change in Hb from baseline to endpoint, first whole-blood or red blood cell transfusion, or study withdrawal. Results. One hundred twenty-nine patients were evaluable for efficacy (FG, n = 41; oral iron, n = 44; no iron, n = 44). Mean increase in Hb was 2.4 g/dl (95% confidence interval [CI], 2.1–2.7) for FG (p = .0092 vs. oral iron; p = .0044 vs. no iron), 1.6 g/dl (95% CI, 1.1–2.1) for oral iron (p =.7695 vs. no iron), and 1.5 g/dl (95% CI, 1.1–1.9) for no iron. Hb response (increase ≥2 g/dl) was 73% for FG (p = .0099 vs. oral iron; p = .0029 vs. no iron), 46% for oral iron (p = .6687 vs. no iron), and 41% for no iron. FG was well tolerated. Conclusion. For cancer patients with chemotherapy-related anemia receiving epoetin alfa, FG produces a significantly greater increase in Hb and Hb response compared with oral iron or no iron, supporting more aggressive treatment with IV iron supplementation for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Self-citationGabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2875 · Cited by 595
Biochemical Markers and Hematologic Indices in the Diagnosis of Functional Iron Deficiency
Thomas, C., & Thomas, L. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.7.1066 · Cited by 492
A randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C. R. V., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 417
Auerbach, M., Ballard, H., Trout, J. R., McIlwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L., & Rana, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.119 · Cited by 414
Self-citationIron, hemochromatosis, and hepatocellular carcinoma
Kowdley, K. V. (2004) · Gastroenterology · doi:10.1016/j.gastro.2004.09.019 · Cited by 391 · cited 1×
“Published reviews on this subjectinpatientswithhemochromatosisreportanincrease in hepatocellular carcinoma only, and typically only in patients who first developed cirrhosis [ 24 ].”
Fishbane, S., Frei, G. L., & Maesaka, J. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90151-5 · Cited by 377
Erythropoietin, iron, and erythropoiesis.
Goodnough, L. T., Skikne, B., & Brugnara, C. (2000) · PubMed · Cited by 310
Erythropoietin, iron, and erythropoiesis
Goodnough, L. T., Skikne, B., & Brugnara, C. (2000) · Blood · doi:10.1182/blood.v96.3.823 · Cited by 300
Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients
Kalantar-Zadeh, K., Regidor, D. L., McAllister, C. J., Michael, B., & Warnock, D. G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005040423 · Cited by 285
Erythropoietin, iron, and erythropoiesis
Goodnough, L. T., Skikne, B., & Brugnara, C. (2000) · Blood · doi:10.1182/blood.v96.3.823.015k49_823_833 · Cited by 273
Use of Recombinant Human Erythropoietin Outside the Setting of Uremia
Cazzola, M., Mercuriali, F., & Brugnara, C. (1997) · Blood · doi:10.1182/blood.v89.12.4248 · Cited by 262
Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans
Faich, G., & Strobos, J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70183-6 · Cited by 208
Michael, B., Coyne, D. W., Fishbane, S., Folkert, V., Lynn, R., Nissenson, A. R., Agarwal, R., Eschbach, J. W., Fadem, S. Z., Trout, J. R., et al. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00314.x · Cited by 199
Strategies for iron supplementation: Oral versus intravenous
Macdougall, I. C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69061.x · Cited by 199
Iron and hepatocellular carcinoma
Deugnier, Y., & Turlin, B. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02430.x · Cited by 147
I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000
(2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)70005-4 · Cited by 136
Nissenson, A. R., Lindsay, R. M., Swan, S. K., Seligman, P. A., & Strobos, J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70184-8 · Cited by 112
Coyne, D. W., Adkinson, F., Nissenson, A. R., Fishbane, S. N., Agarwal, R., Eschbach, J. W., Michael, B., Folkert, V. W., BATLLE, D. C., Trout, J. R., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00703.x · Cited by 98
Self-citationMarkowitz, G. S., Ga, K., Re, F., Coco, M., & Ri, L. (1997) · PubMed · Cited by 96
An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy
Besarab, A., Frinak, S., & Yee, J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1092029 · Cited by 91
Supplemental Iron: A Key to Optimizing the Response of Cancer‐Related Anemia to rHuEPO?
Henry, D. H. (1998) · The Oncologist · doi:10.1634/theoncologist.3-4-275 · Cited by 47
Self-citationIron and infection: Clinical experience
Hoen, B. (1999) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1999.v34.aajkd0344b0030 · Cited by 45
Henry, D. H., & Dahl, N. V. (2007) · Community Oncology · doi:10.1016/s1548-5315(11)70057-2 · Cited by 18
Self-citation
Cited by
Tolkien, Z., Stecher, L., Mander, A. P., Pereira, D. I. A., & Powell, J. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117383 · Cited by 833
Anemia and Patient Blood Management in Hip and Knee Surgery: A Systematic Review of the Literature
Spahn, D. R. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181e08e97 · Cited by 650
The Safety of Intravenous Iron Preparations
Avni, T., Bieber, A., Grossman, A., Green, H., Leibovici, L., & Gafter-Gvili, A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.10.007 · Cited by 441
Detection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Litton, E., Xiao, J., & Ho, K. M. (2013) · BMJ · doi:10.1136/bmj.f4822 · Cited by 394
Metadata
- Authors
- Henry, D. H., Dahl, N. V., Auerbach, M., Tchekmedyian, S., & Laufman, L. R.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02-01
- Volume
- 12
- Issue
- 2
- Pages
- 231-242
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2147159438
- Cited by
- 264
- References
- 28
- FWCI
- 17.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.